Advertisement

Browse Subject Areas

?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

Pharmacoeconomics

Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction

Yi Jing Tan, Stephan Linden, Siew Chin Ong

Industrial prospects on regulatory gaps and barriers in pharmaceutical exports and their counteraction: Local experiential with global implication

Zobia Mubarak, Nasir Abbas, [ ... ], Nadeem Irfan Bukhari

Coping with drug shortages: A study of government-enterprise option cooperation stockpiling strategies for drugs in shortage considering API surrogate stockpiling subsidies

Yipeng Lan, Chenlu Meng, Lihua Sun, Zhe Huang

Medicines prices in International (Geary–Khamis) Dollar. The comparison between regulated and deregulated markets

Tomasz Zaprutko, Julia Cynar, [ ... ], Krzysztof Kus

Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012–19

Hui-Han Chen, Tatenda Yemeke, Sachiko Ozawa

Experience of healthcare personnel on Co-payment mechanism and the implications on its use in private drug outlets in Uganda

Moses Ocan, Racheal Bakubi, [ ... ], Nsobya Sam

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China

Chaoneng He, Xiufang Mi, [ ... ], Haiying Ding

Cost-effectiveness and cost-utility analyses of three different gargles in the treatment of chronic periodontitis

Xin Chen, Wenzhi Niu, Guangyu Hu, Changfeng Chen

Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation

Katharina E. Blankart, Sotiris Vandoros

Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets

Moses Ocan, Winnie Nambatya, [ ... ], Sam Nsobya

Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma

Qiuping Chen, Quan Sun, [ ... ], Jibin Liu

Real-World evidence revelations: The potential of patient support programmes to provide data on medication usage

Eszter Palffy, David John Lewis

Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab

R. J. S. D. Heine, F. W. Thielen, [ ... ], C. A. Uyl-de Groot

Tweets by @plosone

Advertisement

Create a weekly email alert for: Pharmacoeconomics

You can change these options by clicking profile then "Alerts and Notifications"